Transforming CNS treatment
by separating therapeutic power
from impairment

The First Precision Platform
for Inhaled CNS Drugs

A First-in-Class Precision Platform
for Potent CNS Drug Delivery at Home

Syqe Medical is a Pharma-Tech Company Transforming
the Future of Precision Inhaled CNS Drugs Through
a Unique Innovative Inhalation Platform.

Precision Micro-dosing
Patented VaporChip™ enabling pharmaceutical-grade accuracy with 100µg resolution, adjustable by patient or remotely by a physician.

Consistent Absorption
Patented ActiveFlow™ and PulseBreath™ technologies ensure repeatable doses that provide uniform absorption across various inhalation patterns.

Secure & Tamper-Proof
Pre-loaded, electronically tagged cartridges ensure substance integrity and control.

Data-Driven Adherence
Integrated cloud connectivity tracks usage
in real-time, demonstrating ~90% adherence vs.
30-50% with conventional methods.

Syqe Medical's Solution to Resolve the CNS Dose Impairment Tradeoff
READ MORE >>>

Pipeline-In-A-Product

Designed for Rapid Indication Expansion Following DPNP Approval

Preclinical Phase 1 Phase 2 Phase 3 Filed for registration

*Completion expected Q2, 2026. *FDA & EMA expected approval 2031.

DPNP
(Diabetic Peripheral
Nueropathic Pain)

The Strategy
Leverage the core drug-device combination, manufacturing, and regulatory learnings from the DPNP program to rapidly advance subsequent assets (supported by real-world evidence across thousands of patients) into Phase 2, creating a cascade of value.

PTSD
(Post-Traumatic
Stress Disorder)

Lumbar Pain
(Lower Back Pain)

Insomnia

De-Risked by Design:
Validated in the Real World with SyqeAir

We operate a commercial "paid real-world evidence pilot" under localized regulations, generating
Phase 4-level data for our Phase 2 pharma asset.

Overwhelming
RWE

Market
Validation

Commercial Foundation